106 related articles for article (PubMed ID: 11906179)
41. [PTEN: a tumor suppressor with original properties].
Roux P
Bull Cancer; 1999 Jun; 86(6):522-5. PubMed ID: 10417424
[TBL] [Abstract][Full Text] [Related]
42. Transcription of the putative tumor suppressor gene HCCS1 requires binding of ETS-2 to its consensus near the transcription start site.
Zhu JD; Fei Q; Wang P; Lan F; Mao DQ; Zhang HY; Yao XB
Cell Res; 2006 Sep; 16(9):780-96. PubMed ID: 16953216
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis.
Gomez-Manzano C; Fueyo J; Jiang H; Glass TL; Lee HY; Hu M; Liu JL; Jasti SL; Liu TJ; Conrad CA; Yung WK
Ann Neurol; 2003 Jan; 53(1):109-17. PubMed ID: 12509854
[TBL] [Abstract][Full Text] [Related]
44. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas.
Kurose K; Zhou XP; Araki T; Eng C
Genes Chromosomes Cancer; 2000 Oct; 29(2):166-72. PubMed ID: 10959096
[TBL] [Abstract][Full Text] [Related]
45. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.
Ge NL; Rudikoff S
Oncogene; 2000 Aug; 19(36):4091-5. PubMed ID: 10962569
[TBL] [Abstract][Full Text] [Related]
46. Sp1 site is crucial for the mouse claudin-19 gene expression in the kidney cells.
Luk JM; Tong MK; Mok BW; Tam PC; Yeung WS; Lee KF
FEBS Lett; 2004 Dec; 578(3):251-6. PubMed ID: 15589828
[TBL] [Abstract][Full Text] [Related]
47. Cloning and characterization of the promoter region of human LPTS/PinX1 gene.
Wang S; Liao C; Li T; Zhao M
Biochim Biophys Acta; 2004 Feb; 1676(3):261-5. PubMed ID: 14984932
[TBL] [Abstract][Full Text] [Related]
48. Design of a retroviral-mediated ecdysone-inducible system and its application to the expression profiling of the PTEN tumor suppressor.
Stolarov J; Chang K; Reiner A; Rodgers L; Hannon GJ; Wigler MH; Mittal V
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13043-8. PubMed ID: 11687610
[TBL] [Abstract][Full Text] [Related]
49. PTEN and p53: who will get the upper hand?
Trotman LC; Pandolfi PP
Cancer Cell; 2003 Feb; 3(2):97-9. PubMed ID: 12620402
[No Abstract] [Full Text] [Related]
50. Establishment and characterization of nine human brain tumor cell lines.
Shin KH; Choe G; Park YJ; Jang JH; Jung HW; Park JG
In Vitro Cell Dev Biol Anim; 2001; 37(10):625-8. PubMed ID: 11776963
[No Abstract] [Full Text] [Related]
51. Identification of a novel binding partners for tumor suppressor PTEN by a yeast two-hybrid approach.
Gorbenko O; Kuznetsov V; Kukharenko O; Zhyvoloup A; Panasyuk G; Nemazanyy I; Filonenko V; Gout I
Eksp Onkol; 2004 Mar; 26(1):15-9. PubMed ID: 15112574
[TBL] [Abstract][Full Text] [Related]
52. [Characterization of TP53, APC, and PTEN mutational statuses of 120 human cancer cell lines by using yeast-based analyses].
Suzuki G
Hokkaido Igaku Zasshi; 2003 Sep; 78(5):437-49. PubMed ID: 14531287
[No Abstract] [Full Text] [Related]
53. PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors.
Soyoola EO; Pattillo RA
Am J Obstet Gynecol; 2003 Apr; 188(4):S33-6. PubMed ID: 12712134
[TBL] [Abstract][Full Text] [Related]
54. Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region.
Hedberg Oldfors C; Dios DG; Linder A; Visuttijai K; Samuelson E; Karlsson S; Nilsson S; Behboudi A
BMC Genet; 2015 Jul; 16():80. PubMed ID: 26170120
[TBL] [Abstract][Full Text] [Related]
55. Cloning and characterization of the NPCEDRG gene promoter.
Hou D; Guan Y; Liu J; Xiao Z; Ouyang Y; Yu Y; Chen Z
Mol Cell Biochem; 2011 Jan; 346(1-2):1-10. PubMed ID: 20821255
[TBL] [Abstract][Full Text] [Related]
56. PTEN mutations and proteus syndrome.
Eng C; Thiele H; Zhou XP; Gorlin RJ; Hennekam RC; Winter RM
Lancet; 2001 Dec; 358(9298):2079-80. PubMed ID: 11755639
[No Abstract] [Full Text] [Related]
57. The minimal Tumor Suppressor in Lung Cancer-1 promoter is restrained by an inhibitory region.
Hori RT
Mol Biol Rep; 2010 Apr; 37(4):1979-85. PubMed ID: 19653122
[TBL] [Abstract][Full Text] [Related]
58. PTEN mutations and proteus syndrome.
Biesecker LG; Rosenberg MJ; Vacha S; Turner JT; Cohen MM
Lancet; 2001 Dec; 358(9298):2079-80. PubMed ID: 11755638
[No Abstract] [Full Text] [Related]
59. Characterization of the 5'-flanking region of the human TP53 gene and its response to the natural compound, Resveratrol.
Uchiumi F; Shoji K; Sasaki Y; Sasaki M; Sasaki Y; Oyama T; Sugisawa K; Tanuma S
J Biochem; 2016 Apr; 159(4):437-47. PubMed ID: 26684585
[TBL] [Abstract][Full Text] [Related]
60. Proteus syndrome: misdiagnosis with PTEN mutations.
Cohen MM; Turner JT; Biesecker LG
Am J Med Genet A; 2003 Nov; 122A(4):323-4. PubMed ID: 14518070
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
